| Subject |
The Drug Administration of Vietnam has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon |
- Product: ON101, diabetic foot ulcer new drug
- Mass production date: NA
- Effect on company finances and business:
(1)New drug name or code: FESPIXON CREAM
(2)Purpose: Treatment of diabetic foot ulcers.
(3)Planned development stages: The second phase 3 clinical trial(ON101CLCT04) in the US, and other new indications underexploratory studies.
(4)Current development stage:
A.File application/approved/disapproved/Each of clinical trials (include interim analysis):Oneness has been notified by the consultant company that the Drug Administration of Vietnam (DAV) has accepted the NDA application of FESPIXON, the diabetic foot ulcer new drug.
B.Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significantsense, the risks and the associated measures the Company may occur: NA
C.After obtaining official approval or the results (include interim analysis) of statistically significant sense, the future strategy: NA
D.Accumulated investment expenditure incurred: No disclosure of the investment expenditure at the moment in consideration of the future marketing strategies to protect the company and investors interests.
(5)Upcoming development plan:
A.Scheduled completion date: The second phase 3 trial in the US isscheduled to complete in 3 years after initiation
B.Estimate responsibilities: NA
(6)Market: According to the statistics of the International DiabetesFederation (IDF), the population with diabetes in Vietnam have beendoubled in the past 10 years and currently, there are nearly 4 milliondiabetic patients. The associated complications, including foot ulcers,amputation, etc. are also on an increasing trend imposing a huge medicalburden.
FESPIXON has been accepted for NDA review by DAV and will be provided as a novel therapeutic solution to the Vietnamese patients once it is approved in Vietnam in the future.
- Any other matters that need to be specified:
(1)The announcement is with regards to the acceptance by Drug Administrationof Vietnam on NDA application of FESPIXON, the diabetic foot ulcer new drug. The application will be under regulatory and scientific review and shall not be regarded as an approval.
(2)Currently, the health authorities in Singapore, Malaysia, the Philippines, and Vietnam have accepted the NDA application of Fespixon.
(3)According to Article 2 under Guidelines by Taipei Exchange on the Material Information Announced by Listed and OTC Companies, new drug development companies shall make public announcement when filing application for clinical trials or new drug application to domestic or overseas regulatory authorities, receiving approval or disapproval, obtaining the statistical date of endpoints in each clinical trial (including interim analysis), or receiving approval or disapproval on drug license application.
(4)It takes considerable time and expenses to develop a new drug of which success can't be guaranteed. Investors shall bear such investment risk that warrants careful assessment before making investment decisions.
|
